Trial Profile
Retrospective study for predictive and prognostic evaluation of systemic immune-inflammation index (SII) in metastatic renal cell cancer (mRCC) patients treated with first-line sunitinib
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 17 Jul 2015
Price :
$35
*
At a glance
- Drugs Sunitinib (Primary)
- Indications Renal cancer
- Focus Therapeutic Use
- 17 Jul 2015 New trial record
- 02 Jun 2015 Results presented at the 51st Annual Meeting of the American Society of Clinical Oncology.